HCG — PCT / Support

Human Chorionic Gonadotropin (hCG) is a glycoprotein hormone naturally produced by the syncytiotrophoblast cells of the placenta during pregnancy. Its primary physiological role is to maintain the corpus luteum and sustain progesterone production in early gestation. In a research context, hCG is notable for a different property: extensive structural homology with luteinizing hormone (LH), the pituitary gonadotropin that normally signals testosterone production in males.

This structural similarity allows hCG to bind and activate LH/chorionic gonadotropin receptors (LHCGR) expressed on Leydig cells in the testes. The result is direct stimulation of intratesticular testosterone (ITT) synthesis — independent of pituitary LH output. This is the foundation of all AAS research applications: hCG acts at the testicular level and can maintain Leydig cell function even when the hypothalamic-pituitary-testicular axis (HPTA) is fully suppressed by exogenous androgens.

hCG is FDA-approved for the treatment of cryptorchidism and male hypogonadotropic hypogonadism. It is supplied as a lyophilized (freeze-dried) powder that requires reconstitution with bacteriostatic water prior to use. Reconstituted hCG must be stored at 2–8°C and used within 28–30 days; it should never be frozen after reconstitution, as this degrades the protein structure.

Research Applications

• Preventing testicular atrophy during active AAS cycles: Exogenous androgens suppress LH to near-zero within days, halting Leydig cell stimulation. Without LH signaling, intratesticular testosterone falls dramatically and testicular volume decreases over weeks to months. hCG replaces the LH signal directly at the testicular level, maintaining ITT and preserving testicular volume throughout a cycle.
• Leydig cell priming before SERM-based PCT: After prolonged AAS use, Leydig cells become hyposensitive due to prolonged inactivity. A short course of hCG (typically 2–3 weeks) before transitioning to SERM therapy "re-sensitizes" Leydig cells to LH signaling, improving the response to clomiphene- or tamoxifen-driven endogenous LH production. This is the "HCG priming" strategy.
• Male fertility protocols: hCG is the primary pharmacological tool for maintaining or restoring spermatogenesis in research subjects on exogenous testosterone or other AAS. FSH supplementation (via FSH injections or hMG) may be added in refractory cases.

Human chorionic gonadotropin (hCG) is an FDA-approved glycoprotein hormone with indications in female infertility, prepubertal cryptorchidism, and male hypogonadism associated with hypogonadotropic hypogonadism. It acts as an LH analog, directly stimulating testicular Leydig cells to produce testosterone and supporting spermatogenesis via Sertoli cells. Liu PY et al. (2005, J Clin Endocrinol Metab) conducted a dose-response trial of hCG in gonadotropin-deficient men, establishing intratesticular testosterone dose-response relationships. Ramasamy R et al. (2014, J Urol) studied hCG's role in preserving spermatogenesis during TRT, demonstrating that co-administration prevents TRT-induced azoospermia.

hCG use produces a distinctive bloodwork pattern that differs substantially from endogenous LH activity. Understanding these expected changes is essential for interpreting labs during AAS/hCG research protocols.

Practical monitoring note: E2 is the most actionable bloodwork marker during hCG use. Check E2 at baseline and 4–6 weeks into any hCG protocol. Adjust dose or add AI as needed based on E2 level and symptom burden.

Common / Dose-Dependent Effects

• Estradiol elevation: The most clinically relevant side effect. Driven by hCG-stimulated intratesticular aromatase upregulation. At doses above 500 IU per injection, E2 elevation can be substantial and may cause gynecomastia, water retention, mood swings, and reduced libido. A low-dose AI (e.g., anastrozole 0.25–0.5mg twice weekly) is often co-administered at higher hCG doses.
• Testicular pain or swelling: Mild discomfort or a sensation of fullness in the testes is common, particularly when initiating hCG after a period of atrophy. This is a direct consequence of Leydig cell stimulation and typically resolves within days as the testes adapt.
• Mood effects from E2 changes: E2 fluctuations from variable hCG dosing can cause mood instability — irritability, emotional sensitivity, or low mood depending on whether E2 is running high or being over-suppressed by AI co-administration.
• Acne and oily skin: Secondary to increased androgen production (including DHT precursors) stimulated by hCG-driven Leydig cell activity.

Serious / Long-Term Considerations

• Leydig cell desensitization with continuous high-dose use: Prolonged continuous stimulation of LHCGR with supraphysiologic hCG doses leads to receptor downregulation. This paradoxically reduces testosterone production and can impair the testes' ability to respond to both hCG and endogenous LH after discontinuation. Doses above 500 IU per injection and continuous use without breaks significantly increase this risk. Use the minimum effective dose on an intermittent schedule.
• HPTA remains suppressed: hCG does not restore hypothalamic or pituitary function. It bypasses the HPTA entirely. Research subjects who rely solely on hCG without transitioning to SERM-based PCT will remain HPTA-suppressed even after stopping exogenous AAS. hCG is a tool to maintain testicular function — it is not PCT.
• Antibody formation with extended use (rare): As a glycoprotein hormone, hCG carries a theoretical risk of inducing anti-hCG antibodies with prolonged use. These antibodies can cross-react with endogenous LH, potentially impairing future LH sensitivity at the receptor level. This is rare but documented in the literature and represents a hard ceiling on how long continuous hCG courses should run.

With AAS (During Cycle)

• Dosing strategy: 250–500 IU injected 2–3 times per week is the most commonly referenced research dose range for on-cycle testicular maintenance. Lower doses (250 IU 2×/week) are preferred to reduce E2 burden while still preserving Leydig cell function.
• Timing — do not start immediately: Starting hCG at the beginning of an AAS cycle when LH is not yet suppressed offers no benefit and adds unnecessary hormonal burden. Begin hCG 4–6 weeks into a cycle, after HPTA suppression is established. Starting too early also increases cumulative hCG exposure, raising desensitization risk.
• With testosterone: The most common combination. hCG maintains ITT and testicular volume while exogenous testosterone handles systemic androgenic/anabolic effects. E2 management becomes more complex as both testosterone aromatization and hCG-driven intratesticular aromatase contribute to total E2 load.

With SERMs (PCT Transition)

• Sequencing is critical: hCG and SERMs should not be used simultaneously as the primary PCT strategy. hCG suppresses endogenous LH production, which undermines the purpose of SERM therapy (which works by stimulating LH release). Stop hCG 2–3 days before starting a SERM to allow hCG to clear and endogenous LH sensitivity to begin recovering.
• Priming protocol before tamoxifen or clomiphene: After a long or heavy AAS cycle, running hCG at 500 IU EOD for 2–3 weeks (starting after the last AAS injection clears) before beginning SERM therapy prepares Leydig cells for the LH surge that SERMs will generate. This is the theoretical basis for the "hCG priming" approach to PCT optimization.

With Aromatase Inhibitors

• AI co-administration: Low-dose AI (anastrozole 0.25mg 2–3×/week or exemestane 12.5mg EOD) is often added when hCG doses exceed 500 IU/injection or when E2 bloodwork or symptoms indicate elevation. The goal is to blunt intratesticular aromatase output while preserving enough E2 for joint health, libido, and cardiovascular benefit. Avoid over-suppression.

With Testosterone (TRT Context)

• TRT + hCG combination: In TRT research contexts, hCG does not replace exogenous testosterone — it is used alongside it to maintain testicular size, ITT (relevant for fertility), and the intratesticular hormonal environment. This is distinct from the PCT/cycle context. Doses in TRT co-administration protocols are typically lower (250 IU 2×/week).

hCG has a well-established research literature in the context of male reproductive endocrinology, gonadotropin physiology, and AAS-related fertility management.

• Intratesticular testosterone and the maintenance of spermatogenesis
  Coviello AD et al. — Journal of Clinical Endocrinology & Metabolism (2004). Demonstrated that intratesticular testosterone concentrations far exceed serum levels and are critical for spermatogenesis. Showed that low-dose hCG (125 IU EOD) maintains ITT and spermatogenesis during exogenous testosterone administration — a foundational paper for on-cycle hCG protocols in AAS research.
• LH receptor physiology and LHCGR desensitization
  Dufau ML — Annual Review of Physiology (1988). Comprehensive review of LH receptor structure, signal transduction, and the molecular mechanisms of receptor desensitization with continuous gonadotropin stimulation. Provides the mechanistic basis for dose-limiting hCG use to avoid Leydig cell downregulation.
• HCG versus SERMs for male hypogonadism treatment
  Wenker EP et al. — Fertility and Sterility (2015). Comparative analysis of hCG and clomiphene citrate for treatment of secondary hypogonadism. Both increased total testosterone; clomiphene produced higher LH and FSH elevations while hCG produced higher serum testosterone. Relevant to understanding the complementary roles of each agent in HPTA management.
• Recovery of spermatogenesis after AAS use: hCG-based protocols
  Turek PJ et al. — Journal of Urology (1995). Documented recovery of spermatogenesis in AAS users using hCG ± hMG (human menopausal gonadotropin) protocols. Median recovery time to normal sperm counts was 12 months. Established hCG as the first-line pharmacological intervention for AAS-related infertility.
• hCG priming before gonadotropin therapy: mechanistic studies
  Buchter D et al. — European Journal of Endocrinology (1998). Examined whether hCG pre-treatment improves Leydig cell responsiveness prior to combined gonadotropin therapy. Findings supported that prior hCG exposure enhances Leydig cell sensitivity and testosterone output, providing a mechanistic rationale for hCG priming protocols before SERM-based PCT.

• Use the minimum effective dose: The most common research error with hCG is using excessive doses. 250–500 IU 2–3×/week is sufficient for most on-cycle maintenance purposes. Higher doses do not produce proportionally better outcomes and significantly increase E2 burden and Leydig cell desensitization risk. More is not better.
• Reconstitution protocol: Always use bacteriostatic water (not sterile water) for reconstitution. Bacteriostatic water contains benzyl alcohol as a preservative, extending the usable shelf life to 28–30 days at 2–8°C. Sterile water lacks this preservative and results in rapid degradation — typically usable for only 24–72 hours after reconstitution.
• Label every vial: Write the reconstitution date directly on the vial. Reconstituted hCG is a protein hormone that degrades silently — there is no visible change in appearance. Tracking the date is the only way to ensure potency.
• Storage — refrigerate, do not freeze: Keep reconstituted hCG at 2–8°C (standard refrigerator temperature). Freezing after reconstitution denatures the protein structure and destroys bioactivity. Lyophilized (dry powder) hCG vials can be stored at room temperature until reconstitution.
• Monitor E2 at doses above 500 IU/injection: At higher doses, hCG-driven intratesticular aromatase stimulation can produce substantial E2 elevation. Check E2 at 4–6 weeks after initiating or dose-escalating hCG. Symptomatic E2 elevation (sensitivity, water retention, mood effects) warrants dose reduction before adding AI, as AI adds complexity to the hormone management picture.
• Stop hCG 3–4 weeks before completing an AAS cycle: Stopping hCG well before the end of the AAS cycle allows LHCGR sensitivity to reset before PCT begins. If hCG is run to the very end of a cycle, receptor downregulation from recent high-frequency dosing can blunt the PCT response.
• hCG alone is not PCT: This is the most important harm reduction point for researchers new to AAS protocols. hCG maintains Leydig cell function but does not restore hypothalamic GnRH pulsatility or pituitary LH/FSH secretion. HPTA suppression persists during hCG use. A SERM-based transition is required after stopping all androgens and hCG to actually restore the axis.
• Avoid continuous long-duration use: Runs exceeding 10–12 weeks at frequent dosing intervals increase the cumulative LHCGR desensitization burden. If protocol length requires extended use, consider periodic breaks (2–4 weeks off) or dose reduction to maintenance levels rather than continuous therapeutic dosing.